orcabio.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $416.19MM
Orca Bio is the developer of high-precision allogeneic cell therapies designed to safely replace patients’ diseased blood and immune system with a healthy one.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/19/2023 | Series E | $125MM | $xx.xx | $1.44B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,460,468
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
06/17/2020 | Series D | $192MM | $xx.xx | $1.27B | Lightspeed Venture Partners, 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust, IMRF | |
Price per Share
$xx.xx
Shares Outstanding
5,484,883
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Lightspeed Venture Partners, 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust, IMRF
|
||||||
05/17/2018 | Series C | $73.8MM | $xx.xx | $429.31MM | DCVC Bio | |
Price per Share
$xx.xx
Shares Outstanding
6,463,353
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
DCVC Bio
|
||||||
01/01/2017 | Series B-1 | $5.39MM | $xx.xx | $187.99MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,208,618
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
01/01/2017 | Series B | $20MM | $xx.xx | $187.99MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|